tbuckley/cabot-search huggingface dataset:
Interactive Motion-Assisted Exposure Therapy for Veterans with Treatment-Resistant Posttraumatic Stress Disorder: A Randomized Controlled Trial
Authors: Marieke J. van Gelderen, Mirjam J. Nijdam, Joris F.G. Haagen, Eric Vermetten
Journal: Psychotherapy and Psychosomatics (2020)

&lt;b&gt;&lt;i&gt;Background:&lt;/i&gt;&lt;/b&gt; Veterans with posttraumatic stress disorder (PTSD) tend to benefit less from evidence-based treatments than other PTSD populations. A novel virtual reality and motion-assisted exposure therapy, called 3MDR, provides treatment in an immersive, personalized and activating context. &lt;b&gt;&lt;i&gt;Objective:&lt;/i&gt;&lt;/b&gt; To study the efficacy of 3MDR for veterans with treatment-resistant PTSD. &lt;b&gt;&lt;i&gt;Method:&lt;/i&gt;&lt;/b&gt; In a randomized controlled trial (&lt;i&gt;n&lt;/i&gt; = 43) 3MDR was compared to a non-specific treatment component control group. Primary outcome was clinician-rated PTSD symptoms at baseline, after 3MDR, and at the 12-week and 16-week follow-up (primary end point). Intention-to-treat analyses of covariance and mixed models were applied to study differences between groups at the end point and over the course of intervention, controlling for baseline scores. &lt;b&gt;&lt;i&gt;Results:&lt;/i&gt;&lt;/b&gt; The decrease in PTSD symptom severity from baseline to end point was significantly greater for 3MDR as compared to the control group, with a large effect size (&lt;i&gt;F&lt;/i&gt;[1, 37] = 6.43, &lt;i&gt;p&lt;/i&gt; = 0.016, &lt;i&gt;d&lt;/i&gt; = 0.83). No significant between-group difference was detected in the course of PTSD symptoms during treatment when including all time points. The dropout rate was low (7%), and 45% of the patients in the 3MDR group improved clinically. The number needed to treat was 2.86. &lt;b&gt;&lt;i&gt;Conclusions:&lt;/i&gt;&lt;/b&gt; In this trial, 3MDR significantly decreased PTSD symptoms in veterans with, on average, a history of 4 unsuccessful treatments. The low dropout rate may be indicative of high engagement. However, a lack of significant differences on secondary outcomes limits conclusions that can be drawn on its efficacy and underlines the need for larger phase III trials. These data show emerging evidence for 3MDR and its potential to progress PTSD treatment for veterans (Dutch Trial Register Identifier: NL5126).
Kidney Clearance of Secretory Solutes Is Associated with Progression of CKD: The CRIC Study
Authors: Yan Chen, Leila R. Zelnick, Ke Wang, Andrew N. Hoofnagle, Jessica O. Becker, Chi-yuan Hsu, Harold I. Feldman, Rupal C. Mehta, James P. Lash, Sushrut S. Waikar, Tariq Shafi, Stephen L. Seliger, Michael G. Shlipak, Mahboob Rahman, Bryan R. Kestenbaum
Journal: Journal of the American Society of Nephrology (2020)

Significance Statement The secretion of organic solutes by the proximal tubules is an essential intrinsic kidney function. However, the clinical significance of the kidney clearance of tubular secretory solutes is uncertain. In this prospective cohort study of 3416 participants with CKD, the authors found that lower kidney clearances of six endogenous secretory solutes are associated with significantly greater risk of CKD progression (defined as a ≥50% decline in eGFR from baseline, initiation of maintenance dialysis, or kidney transplantation) and that lower clearances of four solutes are associated with all-cause mortality after adjustment for eGFR, albuminuria, and other confounding characteristics. These findings suggest that kidney clearances of secretory solutes may provide complementary information to existing measurements of GFR and albuminuria for the assessment of kidney health. Background The secretion of organic solutes by the proximal tubules is an essential intrinsic kidney function. However, the clinical significance of the kidney’s clearance of tubular secretory solutes is uncertain. Methods In this prospective cohort study, we evaluated 3416 participants with CKD from the Chronic Renal Insufficiency Cohort (CRIC) study. We measured plasma and 24-hour urine concentrations of endogenous candidate secretory solutes at baseline, using targeted liquid chromatography–tandem mass spectrometry. The study defined CKD progression by a ≥50% decline in the eGFR, initiation of maintenance dialysis, or kidney transplantation. We used Cox proportional hazards regression to test associations of secretory-solute clearances with CKD progression and mortality, adjusting for eGFR, albuminuria, and other confounding characteristics. Results Participants in this ancillary study had a mean age of 58 years and 41% were black; the median eGFR was 43 ml/min per 1.73 m 2 . After adjustment, lower kidney clearances of six solutes—kynurenic acid, pyridoxic acid, indoxyl sulfate, xanthosine, isovalerylglycine, and cinnamoylglycine—were associated with significantly greater risks of CKD progression, with clearance of kynurenic acid, a highly protein-bound solute, having the strongest association. Lower clearances of isovalerylglycine, tiglylglycine, hippurate, and trimethyluric acid were significantly associated with all-cause mortality after adjustment. Conclusions We found lower kidney clearances of endogenous secretory solutes to be associated with CKD progression and all-cause mortality, independent of eGFR and albuminuria. This suggests that tubular clearance of secretory solutes provides additional information about kidney health beyond measurements of glomerular function alone.
Technical and imaging factors influencing performance of deep learning systems for diabetic retinopathy
Authors: Michelle Y. T. Yip, Gilbert Lim, Zhan Wei Lim, Quang D. Nguyen, Crystal C. Y. Chong, Marco Yu, Valentina Bellemo, Yuchen Xie, Xin Qi Lee, Haslina Hamzah, Jinyi Ho, Tien-En Tan, Charumathi Sabanayagam, Andrzej Grzybowski, Gavin S. W. Tan, Wynne Hsu, Mong Li Lee, Tien Yin Wong, Daniel S. W. Ting
Journal: npj Digital Medicine (2020)

Deep learning (DL) has been shown to be effective in developing diabetic retinopathy (DR) algorithms, possibly tackling financial and manpower challenges hindering implementation of DR screening. However, our systematic review of the literature reveals few studies studied the impact of different factors on these DL algorithms, that are important for clinical deployment in real-world settings. Using 455,491 retinal images, we evaluated two technical and three image-related factors in detection of referable DR. For technical factors, the performances of four DL models (VGGNet, ResNet, DenseNet, Ensemble) and two computational frameworks (Caffe, TensorFlow) were evaluated while for image-related factors, we evaluated image compression levels (reducing image size, 350, 300, 250, 200, 150 KB), number of fields (7-field, 2-field, 1-field) and media clarity (pseudophakic vs phakic). In detection of referable DR, four DL models showed comparable diagnostic performance (AUC 0.936-0.944). To develop the VGGNet model, two computational frameworks had similar AUC (0.936). The DL performance dropped when image size decreased below 250 KB (AUC 0.936, 0.900, p < 0.001). The DL performance performed better when there were increased number of fields (dataset 1: 2-field vs 1-field-AUC 0.936 vs 0.908, p < 0.001; dataset 2: 7-field vs 2-field vs 1-field, AUC 0.949 vs 0.911 vs 0.895). DL performed better in the pseudophakic than phakic eyes (AUC 0.918 vs 0.833, p < 0.001). Various image-related factors play more significant roles than technical factors in determining the diagnostic performance, suggesting the importance of having robust training and testing datasets for DL training and deployment in the real-world settings.
Use and Costs of Breast Cancer Screening for Women in Their 40s in a US Population With Private Insurance
Authors: Natalia Kunst, Jessica B. Long, Xiao Xu, Susan H. Busch, Kelly A. Kyanko, Ilana B. Richman, Cary P. Gross
Journal: JAMA Internal Medicine (2020)

findings established that many oncologists at US public medical schools receive substantial payments from industry, which are often sizeable in comparison with their annual salaries.Medical schools should enforce their own policies with regard to payment limits.
TCTAP A-065 Impact of Myocardial Infarction on 5-year Clinical Outcomes of Patients with Coronary Chronic Total Occlusion Lesion
Authors: Seung-Woon Rha, Byoung Geol Choi, Se Yeon Choi, Jae Kyeong Byun, Min Shim, Jun Hyuk Kang, Woo Hyeun Kim, Sung Hun Park, Eun Jin Park, Jah Yeon Choi, Sunki Lee, Li Hu, Jin Oh Na, Cheolung Choi, Hong Euy Lim, Jin Won Kim, Eung Ju Kim, Chang Gyu Park, Hong Seog Seo, Dong Joo Oh
Journal: Journal of the American College of Cardiology (2017)
COMPLICATIONS AND OUTCOMES OF BALLOON AORTIC VALVULOPLASTY IN HIGH-RISK OR INOPERABLE PATIENTS
Authors: Itsik Ben-Dor, Augusto D. Pichard, Lowell F. Satler, Yanlin Li, Asmir I. Syed, Gabriel Maluenda, Manuel A. Gonzalez, Sara D. Collins, Cedric Delhaye, Michael A. Gaglia, Kohei Wakabayashi, Nicholas N. Hanna, Rebecca Torguson, Okubagzi Petros, Zhenyi Xue, William O. Suddath, Kenneth M. Kent, Ron Waksman
Journal: Journal of the American College of Cardiology (2010)
TCT-68 Safety and efficacy of stent retriever for the management of acute ischemic stroke. Comprehensive review and meta-analysis
Authors: Konstantinos Marmagkiolis, Abdul Hakeem, Mehmet Cilingiroglu, Cezar Iliescu, Despina Tsitlakidou, Angelos Katramados
Journal: Journal of the American College of Cardiology (2015)
Intravenous Statin Administration During Myocardial Infarction Compared With Oral Post-Infarct Administration
Authors: Guiomar Mendieta, Soumaya Ben-Aicha, Manuel Gutiérrez, Laura Casani, Monika Aržanauskaitė, Francesc Carreras, Manel Sabate, Lina Badimon, Gemma Vilahur
Journal: Journal of the American College of Cardiology (2020)

Beyond lipid-lowering, statins exert cardioprotective effects. High-dose statin treatment seems to reduce cardiovascular complications in high-risk patients. The ideal timing and administration regime remain unknown. This study compared the cardioprotective effects of intravenous statin administration during myocardial infarction (MI) with oral administration immediately post-MI. Hypercholesterolemic pigs underwent MI induction (90 min of ischemia) and were kept for 42 days. Animals were distributed in 3 arms (A): A1 received an intravenous bolus of atorvastatin during MI; A2 received an intravenous bolus of vehicle during MI; and A3 received oral atorvastatin within 2 h post-MI. A1 and A3 remained on daily oral atorvastatin for the following 42 days. Cardiac magnetic resonance analysis (days 3 and 42 post-MI) and molecular/histological studies were performed. At day 3, A1 showed a 10% reduction in infarct size compared with A3 and A2 and a 50% increase in myocardial salvage. At day 42, both A1 and A3 showed a significant decrease in scar size versus A2; however, A1 showed a further 24% reduction versus A3. Functional analyses revealed improved systolic performance in A1 compared with A2 and less wall motion abnormalities in the jeopardized myocardium versus both groups at day 42. A1 showed enhanced collagen content and AMP-activated protein kinase activation in the scar, increased vessel density in the penumbra, higher tumor necrosis factor α plasma levels and lower peripheral blood mononuclear cell activation versus both groups. Intravenous administration of atorvastatin during MI limits cardiac damage, improves cardiac function, and mitigates remodeling to a larger extent than when administered orally shortly after reperfusion. This therapeutic approach deserves to be investigated in ST-segment elevation MI patients.
A COMPARISON OF OUTCOMES WITH CORONARY ARTERY CALCIUM IN UNSELECTED POPULATIONS: THE MULTI-ETHNIC STUDY OF ATHEROSCLEROSIS (MESA) AND HEINZ NIXDORF RECALL STUDY (HNR)
Authors: Matthew J. Budoff, Stefan Mhlenkamp, Robyn McClelland, Joseph Delaney, Marcus Bauer, Heinz Karl Jockel, Hagen Kalsch, Richard Kronmal, Khurram Nasir, Susanne Moebus, Raimund Erbel
Journal: Journal of the American College of Cardiology (2012)
Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax
Authors: Eugen Tausch, Christof Schneider, Sandra Robrecht, Can Zhang, Anna Dolnik, Johannes Bloehdorn, Jasmin Bahlo, Othman Al-Sawaf, Matthias Ritgen, Anna-Maria Fink, Barbara Eichhorst, Karl-Anton Kreuzer, Maneesh Tandon, Kathryn Humphrey, Yanwen Jiang, William Schary, Lars Bullinger, Daniel Mertens, Michele Porro Lurà, Michael Kneba, Hartmut Döhner, Kirsten Fischer, Michael Hallek, Stephan Stilgenbauer
Journal: Blood (2020)
Risk of Prostate Cancer Associated With Familial and Hereditary Cancer Syndromes
Authors: Jennifer L. Beebe-Dimmer, Ashley L. Kapron, Alison M. Fraser, Ken R. Smith, Kathleen A. Cooney
Journal: Journal of Clinical Oncology (2020)

PURPOSE Recently developed clinical guidelines suggest that men in families with specific cancer syndromes, such as hereditary breast and ovarian cancer (HBOC), consider genetic testing, especially in the setting of aggressive disease. However, although a family history (FH) of the same disease among close relatives is an established risk factor for prostate cancer (PC), a direct comparison of PC risk for men with each syndrome in a single population is needed. METHODS The Utah Population Database was used to identify 619,630 men, age ≥ 40 years, who were members of a pedigree that included at least 3 consecutive generations. Each man was evaluated for FH of hereditary PC (HPC), HBOC, and Lynch syndrome (LS) and for his own PC status. PC occurrences (N = 36,360) were classified into one or more subtypes: early onset (EO), lethal, and/or clinically significant. Relative risks (RRs) associated with each subtype, adjusted for important covariables, were calculated in STATA using a modified Poisson regression with robust error variances to obtain corresponding RR CIs for each FH definition. RESULTS An FH of HPC conveyed the greatest relative risk for all PC subtypes combined (RR, 2.30; 95% CI, 2.22 to 2.40), followed by HBOC and LS (both with 1 &lt; RR &lt; 2 and statistically significant). The strongest risks associated with FH were observed for EO disease in all pedigree types, consistent with the contribution of genetic factors to disease occurrence. CONCLUSION In this large, population-based, family database, the risk of PC varied by cancer FH and was most strongly associated with EO disease. These results are critically valuable in understanding and targeting high-risk populations that would benefit from genetic screening and enhanced surveillance.
VISUAL-FUNCTIONAL MISMATCH BETWEEN CORONARY ANGIOGRAPHY AND FRACTIONAL FLOW RESERVE
Authors: Seung-Jung Park, Soo-Jin Kang, Jung-Min Ahn, Eun-Bo Shim, Young-Tae Kim, Sung-Cheol Yoon, Haegeun Song, Jong-Young Lee, Won-Jang Kim, Duk-Woo Park, Seung-Whan Lee, Young-Hak Kim, Cheol Whan Lee, Seong-Wook Park, Seong-Wook Park
Journal: Journal of the American College of Cardiology (2012)
Risk of tuberculosis in rheumatoid arthritis and following anti-TNF treatment. Preliminary results of an ongoing Swedish monitoring-programme of biologics in RA
Authors: J Askling, C M Fored, L Brandt, E Baecklund, L Bertilsson, L Coster, P Geborek, L T Jacobsson, S Lindblad, J Lysholm, Solbritt Rantapää-Dahlqvist, T Saxne, Romanus, L Klareskog, N Feltelius
Journal: Annals of the Rheumatic Diseases (2005)

Risk of tuberculosis in rheumatoid arthritis and following anti-TNF treatment. Preliminary results of an ongoing Swedish monitoring-programme of biologics in RA
Covid-19: FDA approves use of convalescent plasma to treat critically ill patients
Authors: Janice Hopkins Tanne
Journal: BMJ (2020)

<h3>Abstract</h3> Fosfomycin-tromethamine activity is well established for oral treatment of uncomplicated lower urinary tract infections but little is known about its potential efficacy in pyelonephritis. Ascending pyelonephritis was induced in mice infected with 6 strains of <i>Escherichia coli</i> (fosfomycin MICs: 1 μg/ml to 256 μg/ml). Urine pH was 4.5 before infection and 5.5-6.0 during infection. Animals were treated for 24h with fosfomycin (100 mg/kg subcutaneously every 4 hours) and CFU were enumerated in kidneys 24h after the last fosfomycin injection. Peak (20.5 μg/ml at 1h) and trough (3.5 μg/ml at 4h) levels in plasma were comparable to those obtained in human after an oral dose of 3 grams. Fosfomycin treatment significantly reduced bacterial loads in kidneys (3.65 log<sub>10</sub>CFU/g [min-max=1.83-7.03] and 1.88 log<sub>10</sub>CFU/g [1.78-5.74] in start-of-treatment control mice and treated mice, respectively, <i>P</i> &lt; 10<sup>-6</sup>). However, this effect was not found to differ across the 6 study strains (P = 0.71) and between the 3 susceptible and the 3 resistant strains (P=0.09). Three phenomena may contribute to explain this unexpected <i>in vivo</i> activity: i) in mice, fosfomycin kidney/plasma concentrations ratio increased from 1 to 7.8 (95% CI, 5.2; 10.4) within 24 hours; <i>in vitro</i>, when pH decreased to 5: (ii) fosfomycin MICs for the 3 resistant strains (64-256 μg/ml) decreased into the susceptible range (16-32 μg/ml) and: iii) maximal growth rates significantly decreased for all strains and were the lowest in urine. These results suggest that local fosfomycin concentrations and physiological conditions may favour fosfomycin activity in pyelonephritis, even against resistant strains.
Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption
Authors: Donn J. Colby, Michal Sarnecki, Dan H. Barouch, Somporn Tipsuk, Daniel J. Stieh, Eugène Kroon, Alexandra Schuetz, Jintana Intasan, Carlo Sacdalan, Suteeraporn Pinyakorn, Pornsuk Grandin, Hongshuo Song, Sodsai Tovanabutra, Zhanna Shubin, Dohoon Kim, Dominic Paquin-Proulx, Michael A. Eller, Rasmi Thomas, Mark de Souza, Lindsay Wieczorek, Victoria R. Polonis, Amélie Pagliuzza, Nicolas Chomont, Lauren Peter, Joseph P. Nkolola, Johan Vingerhoets, Carla Truyers, Maria G. Pau, Hanneke Schuitemaker, Nittaya Phanuphak, Nelson Michael, Merlin L. Robb, Frank L. Tomaka, Jintanat Ananworanich
Journal: Nature Medicine (2020)
Abstract 10386: LDL-Cholesterol Values Between 2012 and 2017 Suggest Sluggish Adoption of 2013 Guidelines
Authors: Harold R Superko, Paul T Williams, Michael Dansinger, Ernie Schaefer
Journal: Circulation (2018)

Introduction: Over a 14-year period, age-adjusted high blood total cholesterol (≥240 mg/dL) in the US declined from 18.3% in 1999-2000 to 11.0% in 2013-2014, coinciding with the 2001 National Chole...
Abstract 14675: Developing Convolutional Neural Networks for Deep Learning of Ventricular Action Potentials to Predict Risk for Ventricular Arrhythmias
Authors: Anojan Selvalingam, Mahmood Alhusseini, Albert J Rogers, David E Krummen, Firas M Abuzaid, Junaid A Zaman, Tina Baykaner, Paul L Clopton, Peter Bailis, Matei Zaharia, Sanjiv M Narayan
Journal: Circulation (2019)

Background: It is unclear if machine learning can be trained to recognize electrophysiological signal features which represent pathological remodeling in patients with coronary disease (CAD) and le...
Three-dimensional chromatin landscapes in T cell acute lymphoblastic leukemia
Authors: Andreas Kloetgen, Palaniraja Thandapani, Panagiotis Ntziachristos, Yohana Ghebrechristos, Sofia Nomikou, Charalampos Lazaris, Xufeng Chen, Hai Hu, Sofia Bakogianni, Jingjing Wang, Yi Fu, Francesco Boccalatte, Hua Zhong, Elisabeth Paietta, Thomas Trimarchi, Yixing Zhu, Pieter Van Vlierberghe, Giorgio G. Inghirami, Timothee Lionnet, Iannis Aifantis, Aristotelis Tsirigos
Journal: Nature Genetics (2020)
Covid-19: UK lockdown is “crucial” to saving lives, say doctors and scientists
Authors: Gareth Iacobucci
Journal: BMJ (2020)

Medical leaders and scientists have backed the UK government’s decision to impose stringent new restrictions on people’s movement to combat the spread of covid-19.

The prime minister, Boris Johnson, announced new nationwide restrictions on Monday 23 March, telling residents they must leave their home only to travel to work where “absolutely necessary,” to shop for essential items, to exercise once a day, and to access medical care. Shops selling non-essential goods were told to close immediately.

The move came after the government came under increasing pressure to toughen physical distancing measures to help fight the spread of …
TCT-220 Temporal Trends in Chronic Total Occlusion Percutaneous Coronary Interventions: Insights From the PROGRESS-CTO Registry
Authors: Iosif Xenogiannis, Evangelia Vemmou, Fotios Gkargkoulas, Dimitrios Karmpaliotis, Khaldoon Alaswad, Farouc Amin Jaffer, Robert Yeh, Mitul Patel, Ehtisham Mahmud, Michael Megaly, Ilias Nikolakopoulos, Pamela Morley, James Choi, Santiago Garcia, Anthony Doing, Catalin Toma, Barry Uretsky, Oleg Krestyaninov, Dmitrii Khelimskii, Jeffrey W. Moses, Nicholas Lembo, Manish Parikh, Ajay Jayant Kirtane, Ziad Ali, Juan Russo, Aris Karatasakis, Barbara Danek, Bavana Rangan, Shuaib Abdullah, Subhash Banerjee, Emmanouil Brilakis
Journal: Journal of the American College of Cardiology (2019)
IMPLICATIONS OF CONCOMITANT TRICUSPID REGURGITATION IN PATIENTS UNDERGOING TRANSCATHETER AORTIC VALVE IMPLANTATION FOR DEGENERATED SURGICAL AORTIC BIOPROSTHESIS: INSIGHTS FROM PARTNER 2 AORTIC VALVE-IN-VALVE REGISTRY
Authors: Janarthanan Sathananthan, Dale J. Murdoch, Brian R. Lindman, Alan Zajarias, Wael Jaber, Paul Cremer, David Wood, Anson Cheung, Jian Ye, Rebecca T. Hahn, Aaron Crowley, Martin B. Leon, Michael J. Mack, John G. Webb
Journal: Journal of the American College of Cardiology (2018)
TCT-354 Angiographic and Clinical Outcomes after Everolimus-Eluting Stenting for Unprotected Left Main Disease and High Anatomic Coronary Complexity
Authors: Renato Valenti, Angela Migliorini, Ruben Vergara, Guido Parodi, Eleonora Gabrielli, Maria Grazia De gregorio, Elena De Vito, Maria Raffaella Aicale, Nazzario Carrabba, David Antoniucci
Journal: Journal of the American College of Cardiology (2016)
Long-term safety of nine systemic medications for psoriasis: A cohort study using the Spanish Registry of Adverse Events for Biological Therapy in Dermatological Diseases (BIOBADADERM) Registry
Authors: Esteban Daudén, Gregorio Carretero, Raquel Rivera, Carlos Ferrándiz, Mar Llamas-Velasco, Pablo de la Cueva, Isabel Belinchón, Francisco José Gómez-García, Enrique Herrera-Acosta, Diana Patricia Ruiz-Genao, Marta Ferrán-Farrés, Mercè Alsina, Ofelia Baniandrés-Rodríguez, José Luis Sánchez-Carazo, Antonio Sahuquillo-Torralba, Lourdes Rodriguez Fernández-Freire, Jaime Vilar-Alejo, Carmen García-Donoso, José Manuel Carrascosa, Enrique Herrera-Ceballos, José Luis López-Estebaranz, Rafael Botella-Estrada, Eva Segovia-Muñoz, Miguel Angel Descalzo, Ignacio García-Doval, Esteban Daudén, Mar Llamas-Velasco, Gregorio Carretero, Jaime Vilar-Alejo, Raquel Rivera, Carmen García-Donoso, Carlos Ferrándiz, José Manuel Carrascosa, Ferrán Ballescá, Pablo de la Cueva, Isabel Belinchón, Fran J. Gómez-García, Rafael Jiménez, Enrique Herrera-Ceballos, Enrique Herrera-Acosta, José Luis López-Estebaranz, Diana Patricia Ruiz-Genao, Marta Ferrán Farrés, Mercè Alsina, Ofelia Baniandrés, Lula Nieto, José Luis Sánchez-Carazo, Antonio Sahuquillo-Torralba, Rafael Botella-Estrada, Conrad Pujol Marco, Lourdes Rodríguez Fernández-Freire, Almudena Mateu Puchades, Ángeles Flórez Menéndez, Laura Salgado, Beatriz González Sixto, Noemí Eiris, Ignacio García-Doval, Miguel Ángel Descalzo Gallego, Marina de Vega Martínez
Journal: Journal of the American Academy of Dermatology (2020)
TCT-507 Computed Tomography Angiography Versus Angiography for Guiding Percutaneous Coronary Interventions in Bifurcation Lesions – Prospective Randomized Pilot Study
Authors: Rafał Wolny, Jerzy Pregowski, Mariusz Kruk, Cezary Kepka, Artur Debski, Michal Ciszewski, Krzysztof Kukula, Maksymilian Opolski, Zbigniew Chmielak, Adam Witkowski
Journal: Journal of the American College of Cardiology (2016)